Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes

Immunological Reviews

Volumn 188, Issue , 2002, Pages 177-182

  Melief, Cornelis J M ^a   Van der Burg, Sjoerd H ^a   Toes, Rene E M ^a   Ossendorp, Ferry ^a   Offringa, Rienk ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD28 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; LYMPHOCYTE ANTIGEN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OLIGODEOXYNUCLEOTIDE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; HOMING RECEPTOR; IMMUNOGLOBULIN RECEPTOR; LEUKOCYTE ANTIGEN; LIGAND; PEPTIDE FRAGMENT; SUBUNIT VACCINE; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ACTIVATION; CELL MATURATION; CONTROLLED STUDY; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG FORMULATION; HELPER CELL; IMMUNE RESPONSE; LIGAND BINDING; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; WART VIRUS; ACTIVE IMMUNIZATION; APOPTOSIS; CD4+ T LYMPHOCYTE; CHEMISTRY; CYTOTOXICITY; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; NEOPLASM; NEUTROPHIL CHEMOTAXIS; PHYSIOLOGY;

ANTIGEN PRESENTATION; ANTIGENS, CD; ANTIGENS, NEOPLASM; APOPTOSIS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CHEMOTAXIS, LEUKOCYTE; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HUMANS; IMMUNITY, NATURAL; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ACTIVE; LIGANDS; LYMPHOCYTE ACTIVATION; NEOPLASMS; PEPTIDE FRAGMENTS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, LYMPHOCYTE HOMING; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SUBUNIT;

EID: 0036812719     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2002.18816.x     Document Type: Article

References (32)

1. Heath WR, Carbone FR, Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001;19:47-64.
2. Melief CJ, Toes RE, Medema JP, van der Burg SH, Ossendorp F, Offringa R. Strategies for immunotherapy of cancer. Adv Immunol 2000;75:235-282.
3. Qin Z, Noffz G, Mohaupt M, Blankenstein T. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J Immunol 1997;159:770-776.
4. van Stipdonk MJ, Lemmens EE, Schoenberger SR. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol 2001;2:423-429.
5. + T cell differentiation: Initial antigen encounter triggers a developmental program in naive cells. Nat Immunol 2001;2:415-422.
6. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: Implications for vaccine development. Nature Rev Immunol 2002;2:251-262.
7. Alexopoulou L, Holt AC, Medzhitov R, Flayell RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 2001;413:732-738.
8. Arbour NC et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000;25:187-191.
9. Gewirtz AT, Navas TA, Lyons S, Godowski PJ, Madara JL. Cutting edge: Bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol 2001;167:1882-1885.
10. Hemmi H, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002;3:196-200.
11. Hemmi H, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-745.
12. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998;393:480-483.
13. + T-helper and a T-killer cell. Nature 1998;393:474-478.
14. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signaling. Nature 1998;393:478-480.
15. Regnault A, et al. Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 1999;189:371-380.
16. Schuurhuis DH, et al. Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8 + CTL responses in vivo. J Immunol 2002;168:2240-2246.
17. Toes RE, Ossendorp F, Offringa R, Melief CJ. CD4 T cells and their role in antitumor immune responses. J Exp Med 1999;189:753-756.
18. Diehl L, et al. CD40 activation in viva overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Meal 1999;5:774-779.
19. van Mierlo GJ, et al. CD40 stimulation leads to effective therapy of CD40-tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci USA 2002;99:5561-5566.
20. zur Hausen H. Papillomaviruses causing cancer: Evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000;92:690-698.
21. Hendriks J, Gravestein LA, Tesselaar K, van Lier RA, Schumacher TN, Borst J. CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol 2000;1:433-440.
22. Diehl L, et al. In viva triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 costimulatory pathway. J Immunol 2002;168:3755-3762.
23. Bertram EM, Lan P, Watts TH. Temporal segregation of 4-1BB versus CD28-mediated costimulation: 4-1BB ligand influences T cell numbers late in the primary response and regulates the size of the T cell memory response following influenza infection. J Immunol 2002;168:3777-3785.
24. den Boer AT, et al. Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance. J Immunol 2001;167:2522-2528.
25. Zinkernagel RM, Hengartner H. Regulation of the immune response by antigen. Science 2001;293:251-253.
26. Zwaveling S, et al. Established HPV16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002;169:350-358.
27. Takahashi H, Germain RN, Moss B, Berzofsky JA. An immunodominant class I-restricted cytotoxic T lymphocyte determinant of human immunodeficiency virus type 1 induces CD4 class II-restricted help for itself. J Exp Med 1990;171:571-576.
28. + T-cell done; from congenital rubella syndrome patients with IDDM recognize overlapping GAD65 protein epitopes. Implications for HLA class I and II allelic linkage to disease susceptibility. Hum Immunol 1999;60:652-664.
29. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001;107:477-484.
30. Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1999;1:362-368.
31. Lanzavecchia A, Sallusto F. Antigen decoding by T lymphocytes: From synapses to fate determination. Nat Immunol 2001;2:487-492.
32. + T-cell memory. Science 2002;297:2060-2063.